Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP693221.RAmAXrnhtEhTymmvO3eoUZWC1dPe9jeUofgXOzusWF18Y130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP693221.RAmAXrnhtEhTymmvO3eoUZWC1dPe9jeUofgXOzusWF18Y130_assertion type Assertion NP693221.RAmAXrnhtEhTymmvO3eoUZWC1dPe9jeUofgXOzusWF18Y130_head.
- NP693221.RAmAXrnhtEhTymmvO3eoUZWC1dPe9jeUofgXOzusWF18Y130_assertion description "[The anti-CD20 monoclonal antibody rituximab has been less successful in treating chronic lymphocytic leukemia (CLL) than lymphoma, possibly due to the lower density of CD20 on B lymphocytes from CLL patients than on those from lymphoma patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP693221.RAmAXrnhtEhTymmvO3eoUZWC1dPe9jeUofgXOzusWF18Y130_provenance.
- NP693221.RAmAXrnhtEhTymmvO3eoUZWC1dPe9jeUofgXOzusWF18Y130_assertion evidence source_evidence_literature NP693221.RAmAXrnhtEhTymmvO3eoUZWC1dPe9jeUofgXOzusWF18Y130_provenance.
- NP693221.RAmAXrnhtEhTymmvO3eoUZWC1dPe9jeUofgXOzusWF18Y130_assertion SIO_000772 18794139 NP693221.RAmAXrnhtEhTymmvO3eoUZWC1dPe9jeUofgXOzusWF18Y130_provenance.
- NP693221.RAmAXrnhtEhTymmvO3eoUZWC1dPe9jeUofgXOzusWF18Y130_assertion wasDerivedFrom befree-2016 NP693221.RAmAXrnhtEhTymmvO3eoUZWC1dPe9jeUofgXOzusWF18Y130_provenance.
- NP693221.RAmAXrnhtEhTymmvO3eoUZWC1dPe9jeUofgXOzusWF18Y130_assertion wasGeneratedBy ECO_0000203 NP693221.RAmAXrnhtEhTymmvO3eoUZWC1dPe9jeUofgXOzusWF18Y130_provenance.